Genomics Market by Product & Service (System & Software, Consumables, Services), Technology (Sequencing, PCR), Application (Drug Discovery & Development, Diagnostic, Agriculture), End User (Hospital & Clinics, Research Centers) & Region - Global Forecasts to 2025
The global genomics market in terms of revenue was estimated to be worth $22.7 billion in 2020 and is poised to reach $54.4 billion by 2025, growing at a CAGR of 19.0% from 2020 to 2025. Growing government investments to support genomics projects and the growing prevalence of various disorders such as cancer and genetic disorders will propel market growth. Moreover, advancements of NGS in cancer research coupled with the entry of various new players and start-ups in the genomics market are driving the growth of the market. Furthermore, increasing the affordability of genomics technology and improving patient outcomes are expected to boost market growth.
To know about the assumptions considered for the study, Request for Free Sample Report
Genomics Market Dynamics
Drivers: Favorable government initiatives for research on genomics
Governments of various nations are supporting and investing in public and private research institutions. Their focus is to emphasise efforts to resolve the complexity of the human genome, define the genomic basis of human health and disease, and ensure that genomics is used safely to enhance patient care and benefit society through government, public, and private institutions. In recent years, governments in various countries have made significant investments in the field of genomics for the development of new technologies. Listed below are some examples of developments on this front:
- In January 2020, the Department of Biotechnology (DBT) initiated the “Genome India Project” (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some of the areas of focus of this project are precision health, rare genetic disorders, mutation spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research.
- In October 2019, The National Center for Advancing Translational Sciences (NCATS) funded USD 7 million to HudsonAlpha Institute for Biotechnology in Huntsville, Alabama for the research purpose to investigate the application of cutting-edge DNA sequencing technologies that could potentially enhance diagnosis and treatment of many common and rare diseases.
- In September 2019, a whole-genome sequencing project of USD 224 million was created, forming a partnership of pharmaceutical firms and health experts, which will examine and sequence the genetic code of 500,000 volunteers at the UK Biobank, based in Stockport, UK. The project aims to improve health through genetic research and improve the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases, diabetes, arthritis, and dementia.
- In February 2019, the Minister of Science and Sport (Canada) announced funding of USD 22.7 million in addition to funding of USD 33.4 million by provincial governments to support 36 research projects through Genome Canada. The projects include various sectors such as health, agriculture, natural resources, and the environment.
Moreover, favourable regulations from government bodies, a robust number of pipeline projects, and emerging application areas such as aquaculture are opening a new door for market growth.
Opportunities: Adoption of genomics in specialized/personalized medicine
The growing requirement for personalised medicine is also driving the progress of the genomic market. Different people react differently to a particular treatment or disease, and this is the primary reason behind the ballooning popularity of personalised medicine. This approach guarantees better care outcomes. Moreover, it is expected that advancements in the field of gene therapy have the potential to replace traditional drugs and surgeries by enabling doctors to treat a disorder by inserting a gene into a patient’s cell.
Various pharmaceutical companies are increasingly investing in personalised medicine research to develop precision medicine that caters to the specific treatment requirements of patients.
- In 2020, Chigene and MGI signed a cooperation agreement to enable breakthroughs in precision diagnosis using whole-genome sequencing. Under the terms of this agreement, the two companies will leverage their combined advantages in medical testing based on MGI’s gene sequencing platform, DNBSEQ-T7, and Chigene’s big data analysis & storage system to lead the whole-genome sequencing project.
- In 2019, Thermo Fisher Scientific, Inc. (US) introduced the Oncomine Precision Assay, an innovative pan-cancer panel, for its Genexus platform to advance precision medicine in clinical settings.
- In 2018, GlaxoSmithKline plc (UK) entered into a four-year collaboration with 23andMe (US) to use human genetics to guide drug development. It also invested USD 300 million in 23andMe as a part of the collaboration.
Several new products and services have emerged as a result of the trend toward individualised medications and lower sequencing costs due to the launch of NGS technology. With new competitors entering the market, the market is becoming increasingly competitive, and companies are investing in new product launches to increase their revenue and expand their consumer base by gaining a competitive edge over their rivals.
- In June 2021, QIAGEN, a Netherlands-based provider of sample and assay technologies for molecular diagnostics, applied testing, academic, and pharmaceutical research, announced the release of the QIAprep&CRISPR Kit and CRISPR Q-Primer Solutions, which enabled researchers to analyze edited genetic material with unprecedented speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.
Challenges: Shortage of trained professionals
Factors such as the high cost of genomic equipment and the lack of technical know-how about genomics are likely to hinder the market. In certain cases, technological advancements have enabled the instruments in use to present an analysis; however, the interpretation is still dependent on the reader. Due to the complexities involved and the need for in-depth knowledge in the field of genomics, it is necessary to hire trained professionals to analyse and interpret the results of genomic sequencing data. However, owing to the shortage of trained professionals, a number of end-users face significant challenges in analysing genomic data.
By product segment, the consumables segment dominated the market in 2019.
On the basis of product and service, the genomics market is segmented into consumables, systems and software, and services. In 2019, consumables accounted for the largest share of the genomics market. Consumables are widely utilised in genomic systems, and their use will continue to rise with the growing number of genetic tests performed around the globe. The high-volume demand and usage of consumables and the development of various new products in recent years have all contributed to the growth of the segment.
By technology, the sequencing technology segment dominated the market in 2019.
On the basis of technology, the genomics market is segmented into sequencing technologies, PCR, nucleic acid extraction and purification, microarrays, and other technologies. In 2019, the sequencing segment accounted for the largest share of the market. The growth of this segment is driven by its ultra high throughput, scalability, and high speed, which enable researchers to perform a wide variety of applications, including animal breeding, agriculture, and human genomics.
By application, drug discovery and development segment contributed for the largest share of the market in 2019.
On the basis of application, the market is segmented into drug discovery and development, diagnostics, agriculture and animal research, and other applications. Drug discovery and development accounted for the largest application segment share in the genomics market in 2019. The increasing demand for innovative and new therapies for infectious or chronic diseases and the growing focus on quickly developing new therapies are driving the growth in the market. The integration of AI in genomics is accelerating the drug discovery process, reducing turnaround time, offering opportunities, and increasing adoption in the market.
North America accounted for the largest share of the market in 2019.
In 2019, North America accounted for the largest share of the overall market, followed by Europe. This is due to increased government initiatives promoting precision medicine and assisting research institutes and pharmaceutical companies. Moreover, the presence of prominent players and the adoption of several strategies by them to provide efficient genomics solutions through collaboration, new product launches in this region are major driving factors.
The Asia Pacific region is projected to be the fastest growing region over the forecast period
The Asia Pacific region is estimated to grow at the highest CAGR in the genomics market during the forecast period, mainly due to favourable government support for genomics projects, increasing awareness about newer genomics technologies such as NGS, advancements in bioinformatics, and increasing healthcare expenditure in the region. Furthermore, increasing prevalence for the development of drugs for rare diseases, as well as key player expansions to strengthen their market in the APAC region, are driving genomic market growth.
The market is dominated by a few globally established players such as Illumina, Inc. (US), Thermo Fisher Scientific (US) QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and BGI (China).
Genomics Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2020 |
$22.7 billion |
|
Estimated Value by 2025 |
$54.4billion |
|
Growth Rate |
Poised to grow at a CAGR of 19.0% |
|
Largest Share Segments |
The consumables, The sequencing technology, Drug discovery and development |
|
Market Report Segmentation |
By Product & Service, Technology, Application, End User, and Region |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
Genomics Market Report Segmentation
By Product & Service
- Systems & Software
- Consumables
- Services
By Technology
- Sequencing
- PCR
- Nucleic Acid Extraction and Purification
- Microarray
- Other Technologies
By Application
- Drug Discovery and Development
- Diagnostics
- Agriculture and Animal Research
- Other Applications
By End User
- Hospitals & Clinics
- Research Centers and Academic & Government Institutes,
- Pharmaceutical & Biotechnology Companies
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- UK
- Germany
- France
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
-
Rest of the World
- Latin America
- The Middle East and Africa
Recent Developments
- In 2021, Illumina (US) collaborated with Helix OpCo (US) to improve the national surveillance infrastructure in the US so as to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing footprint will significantly expand the country’s existing surveillance efforts to detect and characterize emerging variants of SARS-CoV-2.
- In 2020, BGI (China) expanded its DNA sequencing and laboratory automation products available in Latin America by signing agreements with top distributors in Brazil, Argentina, Peru, Ecuador, Colombia, and Mexico.
- In2020, QIAGEN (Netherlands) acquired NeuMoDx Molecular (US) to strengthen its leadership position in automated molecular testing. Medium- and high-throughput NeuMoDx automation solutions based on PCR testing technology will now be integrated into QIAGEN’s portfolio
- In 2020, Thermo Fisher Scientific (US) launched the Oncomine Myeloid Assay GX.
Frequently Asked Questions (FAQ):
What is the size of Genomics Market ?
The global genomics market crossed $22.7 billion in 2020, and is poised to grow at a CAGR of 19.0% in the next five years to reach $54.4 billion.
Why is Genomics Market Growing?
The genomics market is growing for a number of reasons. First, advances in sequencing technology and data analysis capabilities have made it easier and more cost-effective to study the genome. This has enabled genomics to be used for a wider range of applications, such as medical diagnostics, drug discovery, personalized medicine, and agricultural biotechnology. Additionally, government initiatives and investments in genomics research have driven the growth of the genomics market. Finally, the increasing availability of big data and the emergence of cloud computing have also enabled companies to use genomic data more effectively.
Who all are the prominent players of Genomics Market ?
The market is dominated by a few globally established players such as Illumina, Inc. (US), Thermo Fisher Scientific (US) QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and BGI (China). .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 20)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 25)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 MARKET DATA ESTIMATION AND TRIANGULATION
2.1.4 DATA TRIANGULATION
FIGURE 1 DATA TRIANGULATION METHODOLOGY
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 2 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
FIGURE 3 GENOMICS MARKET SIZE (USD BILLION)
FIGURE 4 MARKET: FINAL CAGR PROJECTIONS (2020−2025)
FIGURE 5 MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 6 MARKET: SEGMENTAL ASSESSMENT
2.3 INDUSTRY INSIGHTS
2.4 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY (Page No. - 33)
FIGURE 7 GLOBAL MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD BILLION)
FIGURE 8 MARKET SHARE, BY TECHNOLOGY, 2019
FIGURE 9 MARKET, BY APPLICATION, 2020 VS. 2025 (USD BILLION)
FIGURE 10 MARKET, BY END USER, 2020−2025
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 37)
4.1 GENOMICS MARKET OVERVIEW
FIGURE 12 INCREASING GOVERNMENT FUNDING TO SUPPORT GENOMICS PROJECTS TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: MARKET, BY APPLICATION & COUNTRY (2019)
FIGURE 13 DRUG DISCOVERY AND DEVELOPMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2019
4.3 GLOBAL MARKET FOR SEQUENCING, BY TYPE
FIGURE 14 NEXT-GENERATION SEQUENCING PROJECTED TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 40)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 GLOBAL MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
5.2.1 DRIVERS
5.2.1.1 Increasing government funding to support genomics projects
5.2.1.2 Growing incidence of cancer and increasing applications of next-generation sequencing in cancer research
TABLE 1 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
5.2.1.3 Entry of new players and start-ups in the genomics market
5.2.1.4 Growing application areas of genomics
5.2.2 OPPORTUNITIES
5.2.2.1 Use of genomics in specialized/personalized medicine
5.2.3 CHALLENGES
5.2.3.1 High cost of genomic equipment
5.2.3.2 Dearth of trained professionals
5.2.3.3 Secure storage of large volumes of sequenced data
5.2.4 TRENDS
5.2.4.1 Partnerships and collaborations for technological advancements in genomics
5.2.4.2 Impact of COVID-19 on the global market
5.3 TECHNOLOGICAL ANALYSIS
TABLE 2 COMPARISON OF SANGER SEQUENCING AND NGS
5.4 VALUE CHAIN ANALYSIS
FIGURE 16 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THE SEQUENCING AND ANALYSIS PHASE
5.5 REGULATORY ANALYSIS
5.5.1 NORTH AMERICA
5.5.1.1 US
TABLE 3 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.5.2 EUROPE
FIGURE 17 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR)
5.5.2.1 Asia Pacific
5.5.2.1.1 China
TABLE 5 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.6 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
FIGURE 18 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
6 GENOMICS MARKET, BY PRODUCT & SERVICE (Page No. - 57)
6.1 INTRODUCTION
TABLE 6 GLOBAL MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
6.2 CONSUMABLES
6.2.1 CONSUMABLES FORM THE LARGEST PRODUCT SEGMENT OF THE GLOBAL MARKET
TABLE 7 GENOMICS CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 8 GENOMICS CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.3 SYSTEMS & SOFTWARE
6.3.1 DECLINING RATES OF GENOME SEQUENCING TO INCREASE THE DEMAND FOR GENOMICS SYSTEMS & SOFTWARE
TABLE 9 GENOMICS SYSTEMS & SOFTWARE MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 10 GENOMICS SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
6.4 SERVICES
6.4.1 HIGH COST OF GENOMIC INSTRUMENTS AND THE POSSIBILITY OF INSTRUMENT OBSOLESCENCE HAVE DRIVEN END USERS TO OUTSOURCE THEIR SEQUENCING NEEDS
TABLE 11 GENOMICS SERVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 12 GENOMICS SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
7 GENOMICS MARKET, BY TECHNOLOGY (Page No. - 65)
7.1 INTRODUCTION
TABLE 13 GLOBAL MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
7.2 SEQUENCING
7.2.1 INCREASING APPLICATIONS OF SEQUENCING IN HUMAN GENOMICS TO DRIVE MARKET GROWTH
TABLE 14 MARKET FOR SEQUENCING, BY REGION, 2018–2025 (USD MILLION)
TABLE 15 GLOBAL MARKET FOR SEQUENCING, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 16 MARKET FOR SEQUENCING, BY TYPE, 2018–2025 (USD MILLION)
7.3 PCR
7.3.1 PCR ALLOWS RESEARCHERS TO PRODUCE MILLIONS OF COPIES OF A SPECIFIC DNA SEQUENCE WITHIN HOURS
TABLE 17 MARKET FOR PCR, BY REGION, 2018–2025 (USD MILLION)
TABLE 18 GLOBAL MARKET FOR PCR, BY COUNTRY, 2018–2025 (USD MILLION)
7.4 NUCLEIC ACID EXTRACTION AND PURIFICATION
7.4.1 ADVANCES IN NUCLEIC ACID EXTRACTION AND PURIFICATION TECHNOLOGIES ARE EXPECTED TO SUPPORT THE GROWTH OF THIS MARKET
TABLE 19 MARKET FOR NUCLEIC ACID EXTRACTION AND PURIFICATION, BY REGION, 2018–2025 (USD MILLION)
TABLE 20 GLOBAL MARKET FOR NUCLEIC ACID EXTRACTION AND PURIFICATION, BY COUNTRY, 2018–2025 (USD MILLION)
7.5 MICROARRAYS
7.5.1 HIGH ADOPTION OF NGS MAY LIMIT THE GROWTH OF MICROARRAY TECHNOLOGIES IN THIS MARKET TO A CERTAIN EXTENT
TABLE 21 MARKET FOR MICROARRAYS, BY REGION, 2018–2025 (USD MILLION)
TABLE 22 GLOBAL MARKET FOR MICROARRAYS, BY COUNTRY, 2018–2025 (USD MILLION)
7.6 OTHER TECHNOLOGIES
TABLE 23 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 24 MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2025 (USD MILLION)
8 GENOMICS MARKET, BY APPLICATION (Page No. - 75)
8.1 INTRODUCTION
TABLE 25 MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
8.2 DRUG DISCOVERY AND DEVELOPMENT
8.2.1 DRUG DISCOVERY AND DEVELOPMENT FORMS THE LARGEST APPLICATION SEGMENT OF THE MARKET
TABLE 26 GENOMICS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 27 MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
8.3 DIAGNOSTICS
8.3.1 GROWING APPLICATIONS OF GENOMICS IN THE DIAGNOSTICS FIELD TO PROPEL MARKET GROWTH
TABLE 28 GRANTS, BY CANCER TYPE (AS OF OCTOBER 2020)
TABLE 29 MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 30 GLOBAL MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 31 MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
8.4 AGRICULTURE AND ANIMAL RESEARCH
8.4.1 GENOMICS HELPS IN IMPROVING THE PRODUCTIVITY OF CROPS AND LIVESTOCK—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 32 MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 33 GENOMICS MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 34 MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 35 MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
9 GENOMICS MARKET, BY END USER (Page No. - 85)
9.1 INTRODUCTION
TABLE 36 MARKET, BY END USER, 2018–2025 (USD MILLION)
9.2 HOSPITALS & CLINICS
9.2.1 INCREASING DEMAND FOR PHARMACOGENOMICS TO DRIVE THE ACCEPTANCE OF NGS IN HOSPITALS
TABLE 37 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018–2025 (USD MILLION)
TABLE 38 GENOMICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2018–2025 (USD MILLION)
9.3 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
9.3.1 INCREASE IN RESEARCH INTENSITY TO DRIVE THE USAGE OF GENOMICS PRODUCTS AMONG ACADEMIC & GOVERNMENT INSTITUTES
TABLE 39 MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018–2025 (USD MILLION)
TABLE 40 GLOBAL MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 GROWING IMPORTANCE OF BIOMARKERS TO DRIVE THE USE OF GENOMICS PRODUCTS & SERVICES AMONG PHARMA & BIOTECH COMPANIES
TABLE 41 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 42 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
9.5 OTHER END USERS
TABLE 43 MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 44 MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
10 GENOMICS MARKET, BY REGION (Page No. - 93)
10.1 INTRODUCTION
FIGURE 19 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD
TABLE 45 GLOBAL MARKET, BY REGION, 2018–2025 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 20 NORTH AMERICA: GENOMICS MARKET SNAPSHOT
TABLE 46 NORTH AMERICA: MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 48 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.2.1 US
10.2.1.1 US dominates the North American genomics market
TABLE 51 US: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 52 US: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 53 US: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 54 US: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing research in the field of genomics to drive market growth
TABLE 55 CANADA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 56 CANADA: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 57 CANADA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 58 CANADA: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3 EUROPE
TABLE 59 EUROPE: GENOMICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 60 EUROPE: MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 61 EUROPE: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 62 EUROPE: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 63 EUROPE: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.1 UK
10.3.1.1 Availability of government funding and strategic collaborations with biotech firms to boost the market
TABLE 64 UK: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 65 UK: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 66 UK: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 67 UK: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Increasing awareness of NGS in the country to boost the market growth in Germany
TABLE 68 GERMANY: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 69 GERMANY: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 70 GERMANY: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 71 GERMANY: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government investments in genomics to boost the growth of the French genomics market
TABLE 72 FRANCE: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 73 FRANCE: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 74 FRANCE: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 75 FRANCE: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.3.4 ROE
TABLE 76 ROE: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 77 ROE: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 78 ROE: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 79 ROE: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 21 ASIA PACIFIC: GENOMICS MARKET SNAPSHOT
TABLE 80 ASIA PACIFIC: MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 81 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 82 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 84 ASIA PACIFIC: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.1 CHINA
10.4.1.1 China is expected to command the largest share of the Asia Pacific market
TABLE 85 CHINA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 86 CHINA: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 87 CHINA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 88 CHINA: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Growing conferences and workshops on newer genomics technologies such as NGS to increase awareness and drive the market
TABLE 89 JAPAN: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 90 JAPAN: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 91 JAPAN: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 92 JAPAN: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Emergence of local players & increasing adoption of genomics technologies is expected to aid the growth of the genomics market in India
TABLE 93 INDIA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 94 INDIA: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 95 INDIA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 96 INDIA: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 97 ROAPAC: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 98 ROAPAC: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 99 ROAPAC: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 100 ROAPAC: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 101 ROW: GENOMICS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 102 ROW: MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 103 ROW: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 104 ROW: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 105 ROW: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Expansions of key players in Latin American regions to boost the market
TABLE 106 LATIN AMERICA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 107 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 108 LATIN AMERICA: GENOMICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 109 LATIN AMERICA: MARKET, BY END USER, 2018–2025 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Increasing adoption of genetic testing in the Middle East and rising HIV & cancer incidence in Africa are driving market growth
TABLE 110 MIDDLE EAST & AFRICA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA: GENOMICS MARKET, BY END USER, 2018–2025 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 130)
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS
FIGURE 22 GENOMICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
11.3 MARKET EVALUATION FRAMEWORK
TABLE 114 MARKET EVALUATION FRAMEWORK: PRODUCT & SERVICE LAUNCHES —THE MAJOR STRATEGY ADOPTED BY PLAYERS
11.4 COMPETITIVE BENCHMARKING
11.4.1 ANALYSIS OF THE PRODUCT PORTFOLIO OF MAJOR PLAYERS IN THE GENOMICS MARKET
11.5 COMPETITIVE SCENARIO
11.5.1 KEY PRODUCT LAUNCHES
11.5.2 KEY COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS
11.5.3 KEY EXPANSIONS
11.5.4 KEY ACQUISITIONS
11.6 COMPANY EVALUATION MATRIX
11.6.1 GLOBAL GENOMICS MARKET: COMPANY EVALUATION MATRIX (OVERALL MARKET) (2019)
11.6.1.1 Stars
11.6.1.2 Emerging leaders
11.6.1.3 Pervasive players
11.6.1.4 Participants
FIGURE 23 GLOBAL GENOMICS MARKET: COMPANY EVALUATION MATRIX, 2019
11.6.2 COMPETITIVE LEADERSHIP MAPPING (START-UPS) (2019)
11.6.2.1 Progressive companies
11.6.2.2 Starting blocks
11.6.2.3 Dynamic companies
11.6.2.4 Responsive companies
FIGURE 24 COMPETITIVE LEADERSHIP MAPPING: GENOMICS MARKET
12 COMPANY PROFILES (Page No. - 139)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 MAJOR PLAYERS
12.1.1 ILLUMINA, INC.
FIGURE 25 ILLUMINA, INC.: COMPANY SNAPSHOT (2019)
12.1.2 THERMO FISHER SCIENTIFIC, INC.
FIGURE 26 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
12.1.3 QIAGEN N.V.
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
12.1.4 AGILENT TECHNOLOGIES
FIGURE 28 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2020)
12.1.5 F. HOFFMANN-LA ROCHE, LTD.
FIGURE 29 F. HOFFMANN-LA ROCHE, LTD.: COMPANY SNAPSHOT (2019)
12.1.6 BIO-RAD LABORATORIES, INC.
FIGURE 30 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2019)
12.1.7 EUROFINS SCIENTIFIC
FIGURE 31 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2019)
12.1.8 OXFORD NANOPORE TECHNOLOGIES
12.1.9 BGI
12.1.10 DANAHER CORPORATION
FIGURE 32 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
12.1.11 EPPENDORF AG
FIGURE 33 EPPENDORF AG: COMPANY SNAPSHOT (2019)
12.1.12 MERCK KGAA
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2019)
12.1.13 NEW ENGLAND BIOLABS
12.1.14 PROMEGA CORPORATION
12.1.15 CREATIVE BIOGENE
12.1.16 START-UP/SME PLAYERS
12.1.16.1 Novogene Co., Ltd.
12.1.16.2 Helix OpCo, LLC
12.1.16.3 23andMe, Inc.
12.1.16.4 Personal Genome Diagnostics Inc. (PGDx)
12.1.16.5 Personalis, Inc.
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 185)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global genomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the genomics market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study included publications from government sources such as the International Chromosome and Genome Society (ICGS), International Mammalian Genome Society (IMGS), International Agency for Research on Cancer (IARC), National Human Genome Research Institute (NHGRI), International Service for Acquisition of Agri-Biotech Applications (ISAAA), Genome Canada, European Society of Human Genetics (ESHG), Genomics England, Centre for Cellular & Molecular Biology (India) (CCMB), Japan Agency for Medical Research and Development, Kinghorn Centre for Clinical Genomics (Australia) (KCCG), King Abdulaziz City for Science and Technology (KACST), and São Paulo Research Foundation (FAPESP).
Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations, among others. Secondary data was collected and analyzed to arrive at the overall size of the global genomics market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global genomics market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from hospitals & clinics, research centers, government & academic institutes, and pharmaceutical & biopharmaceutical companies) and supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the overall size of the genomics market through the methodology mentioned above, this market was split into several segments and subsegments. Market breakdown procedures were employed, wherever applicable, to arrive at the exact market value for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Report Objectives
- To define, describe, and forecast the genomics market on the basis of product & service, application, technology, end user, and region
- To provide detailed information regarding the factors influencing the market growth (such as drivers, opportunities, challenges, and trends)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall genomics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To profile the key players in the global genomics market and comprehensively analyze their core competencies and market rankings
- To forecast the size of the market segments in North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)
- To track and analyze competitive developments such as product launches, product approvals, product enhancements, expansions, acquisitions, partnerships, collaborations, and agreements in the genomics market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the European genomics market into RoE countries
- Further breakdown of the Asia Pacific genomics market into RoAPAC countries
- Further breakdown of the Rest of the World (RoW) genomics market into Mexico, Argentina, and the RoW countries
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
Growth opportunities and latent adjacency in Genomics Market
I am looking for detailed market size valuation pointers for the Genomics Market from 2025 to 2030. Is this data included in your study?
Can you elaborate more on the global growth dynamics of the Genomics Market?
Which are the major building blocks for the global growth of Genomics Market?
Which of the geographical segment holds the major share of the Genomics Market?